US FDA Gets Out Of The 'Competition' Business – At Least In Oncology
Executive Summary
The US FDA often reminds advisory committees that price is not part of its mission, but the agency pointedly told the experts meeting to review Lilly/Innovent’s sintilimab that “competition” should not be a factor either. Do they really mean that?
You may also be interested in...
Lack Of Competition Equals Higher Drug Prices: HHS Analysis Is Slogan In Search Of Solutions
Findings could provide a basis for future policy interventions, the department says. Speeding generics and biosimilars would seem a natural outshoot of the conclusions, but the report does not contain any recommendations.
Going Global Gets Stuck, Chinese Drug Makers CRL Show What Not To Do
Chinese drug makers have more to lament and plenty to learn from as Junshi, HutchMed follow Innovent Bio with FDA rejections. A holistic not opportunistic approach is needed, one ex-FDA expert suggests.
No Love: Chinese Oncology Firms Scramble To Cope With New US Reality
After a high-profile FDA advisory committee rejection of potentially the first "Made In China" cancer drug in the US, from Innovent Bio and partner Lilly, many Chinese oncology companies are now quietly looking for the next step forward.